Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sofinnova Ventures' New $440M Eighth Fund Exceeds Expectations And Makes Adjustments

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm wins higher commitments from limited partners, turning its health-care focus to late stage companies and forgoing high-tech investments.

You may also be interested in...

Vicept Management, VCs Team Up Again To Launch Aclaris With $21M

Newly launched dermatology start-up Aclaris brings the band back together, as Vicept’s core management and VCs begin a new endeavor in a sometimes-neglected sector.

Pain At The Pump: For Some VCs, Filling Up On Cash Is Easier Than For Others

Who has recently topped up, and who’s running on empty? START-UP’s annual gas-tank review of venture fundraising shows how consolidation has hit the sector hard in the past twelve months, as limited partners concentrate their money in specialized funds that have demonstrated an ability to deliver returns.

Euro Crisis Hits Investor Risk Appetite, But Opportunities Remain

There are good-value opportunities in Europe for VCs with money to invest, but those seeking new funds face an unprecedentedly tough challenge that’s compounded by euro uncertainty.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts